Dechra beats expectations as Eurovet pushes profits
4th Sep 2012 07:25
The veterinary pharmaceuticals firm Dechra has revealed growing sales across all its major brands and profits ahead of market forecasts for the full year to the end of June. Group revenue to the end of June increased by 9.5% compared to 2011, from £389.2m to £426m. That figure is also ahead of mark
Read moreTuesday preview: Genus, Dechra, Greene King
3rd Sep 2012 16:34
Tuesday has a bit of an agricultural feel to it, with animal genetics company Genus and veterinary health-care company Dechra Pharmaceuticals set to update the market. Peel Hunt says emerging markets growth should be offsetting higher feed prices at Genus. It is forecasting a 15% improvement in pr
Read moreWeek Ahead: Central banks, Morrisons, Genus
31st Aug 2012 09:48
Central bank decisions will be in focus next week, particularly in the wake of the central bankers' economic symposium in Jackson Hole. Indeed, so busy is European Central Bank (ECB) President Mario Draghi preparing for next week's meeting that he has been unable to attend the jolly-up in the Wyomi
Read moreDechra no dog as revenues rise
10th Jul 2012 09:10
Revenues are on the rise at Dechra Pharmaceuticals although the veterinary healthcare company is still experiencing supply issues in the US. Group revenue for the year ended June 30th was around 9.3% ahead of the prior year. On a like-for-like basis, which excludes the acquisition of Eurovet Animal
Read moreTuesday broker round-up - UPDATE
10th Jul 2012 08:18
WPP: JP Morgan upgrades to outperform from neutral. AMEC: BarCap raises target from 1,340p to 1,350p, underweight rating kept. ASOS: Peel Hunt keeps buy rating and 1,800p target. AstraZeneca: BarCap keeps equal weight rating. Betfair: Nomura cuts target from 1,070p to 946p, buy rating unchanged.
Read moreDebenhams boss rings up 100,000 shares
23rd May 2012 16:19
Michael Sharp, the man who took over retail chain Debenhams last year, has underlined his faith in the company with the purchase of shares 100,000 shares. The £74,000 purchase saw the Chief Executive Officer invest his money at 74.32p a go, increasing his interest in the company to over 5.95m share
Read moreAdmiral CFO in share disposal
18th Apr 2012 14:14
Kevin Chidwick, Chief Financial Officer of Admiral, the FTSE 100 car insurance group, has sold off a chunk of shares awarded to him through the firm's senior executive restricted share plan. Chidwick, 48, offloaded 34,207 shares at 1,179.00p each for a total of £403,301. The director also retained
Read moreDechra Pharmaceuticals to acquire vetinary pharmaceuticals firm
5th Apr 2012 12:19
Dechra Pharmaceuticals has agreed to conditionally acquire the entire issued share capital of Eurovet Animal Health, a vetinary pharmaceuticals business. The business will be purchased for €135m (around £112.5m) on a debt-free, cash-free basis. The acquisition will be funded using the proceeds of
Read moreThursday broker round-up - UPDATE
5th Apr 2012 08:00
Antofagasta: AlphaValue upgrades from reduce to add, target cut from 1,233.6p to 1,211.5p. Aveva: Merchant Securities raises target from 1,785p to 1,800p, buy rating kept. Ashmore: UBS upgrades from neutral to buy, target lifted from 400p to 420p. Barclays: AlphaValue upgrades from reduced to add
Read moreMargins squeezed in Dechra's Services business
21st Feb 2012 12:07
Veterinary pharmaceutical firm Dechra Pharmaceuticals saw a slight fall in interim pre-tax profits and a softening of gross margins in its Services division in the second half of 2011. Profit before tax in the six months to December 31st 2011 dropped to £8.9m from £9m the year before, on revenues o
Read moreTuesday broker round-up - UPDATE
21st Feb 2012 09:00
Admiral: Nomura reiterates buy recommendation and 1,100p target; Credit Suisse upgrades to outperform from neutral, lifts target from 1,100p to 1,300p. Morrison: Goldman Sachs adds to conviction sell list. Petropavlovsk: Nomura upgrades from reduce to neutral, target upped from 860p to 910p. Aber
Read moreTuesday broker round-up - UPDATE
31st Jan 2012 09:32
ARM Holdings: Nomura keeps neutral rating and 580p target; Nomura maintains hold rating and 575p target; Peel Hunt keeps hold and 580p target. National Grid: Nomura reiterates buy rating and 700p target. British Sky Broadcasting: Nomura keeps buy recommendation and 1,000p target; Peel Hunt maintai
Read moreMargins under pressure at Dechra
11th Jan 2012 13:10
Veterinary pharmaceutical firm Dechra Pharmaceuticals has reported that group revenue for the six months ended 31 December was around 9.1% ahead of the equivalent period last year. In European Pharmaceuticals the group achieved revenue growth of around 10.5% (7.8% at constant currency) compared to
Read moreWednesday broker round-up - UPDATE
11th Jan 2012 08:56
Unilever: Bank of America Merrill Lynch downgrades to underweight from neutral. Aggreko: Credit Suisse downgrades to neutral from outperform. Capita: Citi upgrades to buy from neutral. Reckitt Benckiser: Morgan Stanley upgrades to overweight from neutral. Rentokil: RBC upgrades to top-pick fr
Read moreSunday share tip round-up: Dechra, Aveva, Persimmon
6th Nov 2011 17:27
The first three months of the financial year started well at animal health-care group Dechra. Revenue in the first quarter is 7.7% ahead of the same period last year, whereas consensus for the current year is for revenues to rise 4.7%, so this result looks good. Particularly heartening for The Sunda
Read more